Thus, Mihara and his team developed an anti-CD38 CAR, and demonstrated that these CD38-specific T cells effectively eliminate B-NHL cells both in vivo and in vitro [102]. The gene discussed is CD38; the disease is non-Hodgkin lymphoma.